Taking The ‘O’ Out Of RTOR: US FDA’s Real-Time Review Primed For Expansion Beyond Oncology
Executive Summary
Technology modernization efforts, the expansion of cloud-based submission capabilities, and the ongoing COVID-19 pandemic could serve as catalysts to broaden FDA’s Real-Time Oncology Review program beyond cancer therapeutics, Pfizer exec Richard Jahn says.
You may also be interested in...
Candidates For The US FDA’s STAR Program Might As Well Be Breakthrough Therapies, Too
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.
BsUFA III Talks Could Move Cloud-Platform Goals Forward
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
Inspection Questions Delay CBER’s Embrace Of Real-Time Oncology Review
The oncology branch of the US FDA’s biologics center does not believe RTOR would speed application reviews.